Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Share-based Compensation (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Share-based Compensation for 12 consecutive years, with $53000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 65.81% year-over-year to $53000.0, compared with a TTM value of $334000.0 through Sep 2025, down 38.03%, and an annual FY2024 reading of $512000.0, down 28.59% over the prior year.
  • Share-based Compensation was $53000.0 for Q3 2025 at Arcadia Biosciences, down from $86000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $541000.0 in Q4 2021 and bottomed at $53000.0 in Q3 2025.
  • Average Share-based Compensation over 5 years is $217263.2, with a median of $199000.0 recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 173.23% in 2021, then crashed 65.81% in 2025.
  • Year by year, Share-based Compensation stood at $541000.0 in 2021, then crashed by 61.37% to $209000.0 in 2022, then tumbled by 31.1% to $144000.0 in 2023, then decreased by 18.75% to $117000.0 in 2024, then plummeted by 54.7% to $53000.0 in 2025.
  • Business Quant data shows Share-based Compensation for RKDA at $53000.0 in Q3 2025, $86000.0 in Q2 2025, and $78000.0 in Q1 2025.